# Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC

> **NCT03644823** · PHASE2 · TERMINATED · sponsor: **Oslo University Hospital** · enrollment: 21 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Atezolizumab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT03644823
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-15
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** slow recruiting
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03644823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03644823, "Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03644823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*